Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.
Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C. Nachman S, et al. Among authors: hafner r. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. Lancet Infect Dis. 2015. PMID: 25957923 Free PMC article. Review.
Viewpoint: Challenges and opportunities in tuberculosis research.
Kim PS, Makhene M, Sizemore C, Hafner R. Kim PS, et al. Among authors: hafner r. J Infect Dis. 2012 May 15;205 Suppl 2(Suppl 2):S347-52. doi: 10.1093/infdis/jis190. Epub 2012 Mar 22. J Infect Dis. 2012. PMID: 22448021 Free PMC article. No abstract available.
Drug-resistant tuberculosis: time for visionary political leadership.
Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. Abubakar I, et al. Among authors: hafner r. Lancet Infect Dis. 2013 Jun;13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6. Epub 2013 Mar 24. Lancet Infect Dis. 2013. PMID: 23531391 Free article. Review.
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G; AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team. Dooley KE, et al. Among authors: hafner r. Lancet Infect Dis. 2021 Jul;21(7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12. Lancet Infect Dis. 2021. PMID: 33587897 Free PMC article. Clinical Trial.
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
Gausi K, Chirehwa M, Ignatius EH, Court R, Sun X, Moran L, Hafner R, Wiesner L, Rosenkranz SL, de Jager V, de Vries N, Harding J, Gumbo T, Swindells S, Diacon A, Dooley KE, McIlleron H, Denti P. Gausi K, et al. Among authors: hafner r. J Antimicrob Chemother. 2022 Aug 25;77(9):2489-2499. doi: 10.1093/jac/dkac188. J Antimicrob Chemother. 2022. PMID: 35678468 Free PMC article.
264 results